• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Enterome Unveils Enhanced Interim Phase 2 Data For Oncomimics

    GLOBENEWSWIRE

    Enterome`s EO2401 Demonstrates Survival Benefit in Phase 2 GBM

    GLOBENEWSWIRE

    Enterome`s Oncomimics™ EO2463 Granted FDA Fast Track Designation

    GLOBENEWSWIRE

    Enterome Shares Positive Ph2 Results for EO2463 in iNHL

    GLOBENEWSWIRE

    Enterome raises $19M for OncoMimics™ to treat Follicular Lymphoma

    GLOBENEWSWIRE

    Enterome to present Phase 2 data for OncoMimics EO2463 at ICML

    GLOBENEWSWIRE

    Enterome`s Ph1/2 MSS Colorectal Cancer Data For EO4010 At ASCO

    GLOBENEWSWIRE

    Enterome Presents Data For Colorectal Cancer At ESMO IO 2024

    GLOBENEWSWIRE

    Enterome EO2463 Shows Early Response In Follicular Lymphoma

    GLOBENEWSWIRE

    Enterome Hosts Webinar on Phase 1/2 Data for EO2463

    BUSINESSWIRE

    Enterome to Present EO2463 Data at ASH Annual Meeting 2024

    GLOBENEWSWIRE

    Enterome to Present EO2463 Data in B-cell Lymphoma at ASCO 2024

    GLOBENEWSWIRE

    Enterome Announces Successful Completion of Phase 2 ROSALIE Study

    GLOBENEWSWIRE

    Enteromes Immunotherapy EO2401 Improves Survival Rate in Glioblastoma

    GLOBENEWSWIRE

    Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of EO2401

    GLOBENEWSWIRE

    Enterome Presents Immune-Monitoring Data on EO2401

    GLOBENEWSWIRE

    Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401

    GLOBENEWSWIRE

    Enterome to Present Data on EO2401 in Adrenal Tumors at ESMO

    GLOBENEWSWIRE

    Enterome announces first patient dosed in Phase 2 trial with EO2040

    GLOBENEWSWIRE

    Enterome announces first patient dosed in a Ph1/2 trial third OncoMimics, EO4010

    GLOBENEWSWIRE

    Enterome`s EO2463, demonstrates early efficacy in Phase 1/2 trial

    GLOBENEWSWIRE

    Enterome announces sustained positive clinical outcomes with EO2401

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.